Closing in on an oral treatment

Roland Martin
Additional contact information
Roland Martin: Roland Martin is at the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research, University Medical Center-Eppendorf, D-20251 Hamburg, Germany. roland.martin@zmnh.uni-hamburg.de

Nature, 2010, vol. 464, issue 7287, 360-361

Abstract: At present, only injectable drugs are available for treating multiple sclerosis. So clinical trials indicating that the drug fingolimod might be a step towards an oral treatment for the disease are exciting indeed.

Date: 2010
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/464360a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:464:y:2010:i:7287:d:10.1038_464360a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/464360a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().